Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Effect of PD-1 inhibition on macrophage population in human tissue cultures.
Authors
Ngoc Hoang
University Cancer Center Leipzig, Leipzig, Germany;
Ngoc Hoang , Charlotte Welling , Marlon Husstegge , Justus Koerfer , Astrid Monecke , Arved Weimann , Ines Gockel , Florian Lordick , Sonja Kallendrusch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 463)
DOI
10.1200/JCO.2023.41.4_suppl.463
Abstract #
463
Poster Bd #
L9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2016 Genitourinary Cancers Symposium
Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).
First Author: Guillermo de Velasco
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita